Breaking News Instant updates and real-time market news.

VSAT

ViaSat

$72.72

0.46 (0.64%)

, EXC

Exelon

$40.80

-0.015 (-0.04%)

10:22
12/15/17
12/15
10:22
12/15/17
10:22

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Simon Flannery started ViaSat (VSAT) with an Equal Weight rating and $78 price target. 2. Cantor Fitzgerald analyst Elemer Piros initiated Rigel Pharmaceuticals (RIGL) with an Overweight rating and $6 price target, sayign the company is poised to achieve FDA approval of fostamatinib for lead indication immune thrombocytopenia. 3. Exelon (EXC) analyst Paul Fremont initiated Exelon with an Underperform and $36 price target to reflect expected earnings pressure from weak forward gas and power prices and high debt. 4. Credit Suisse analyst Gregory Lewis started Ocean Rig UDW (ORIG) with an Outperform rating and $32 price target, stating that the company's restructuring wiped away $3.3B in debt. 5. Barclays analyst Amir Rozwadowski started Frontier Communications (FTR) with an Underweight rating and $7 price target, as he believes the company's dividend is at risk of being cut further over the near term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

VSAT

ViaSat

$72.72

0.46 (0.64%)

EXC

Exelon

$40.80

-0.015 (-0.04%)

ORIG

Ocean Rig UDW

$24.55

-0.17 (-0.69%)

FTR

Frontier Communications

$8.69

-1.51 (-14.80%)

RIGL

Rigel Pharmaceuticals

$3.57

-0.15 (-4.03%)

  • 17

    Apr

VSAT ViaSat
$72.72

0.46 (0.64%)

12/15/17
MSCO
12/15/17
INITIATION
Target $78
MSCO
Equal Weight
ViaSat initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Simon Flannery started ViaSat with an Equal Weight rating and $78 price target, stating that cash generation is still several years away and that its pending ViaSat-3 launches will leave execution risk lingering until 2020 or later.
11/10/17
NEED
11/10/17
UPGRADE
Target $78
NEED
Buy
ViaSat upgraded to Buy at Needham on imminent ViaSat-2 launch
As reported earlier, Needham analyst Richard Valera upgraded ViaSat to Buy from Hold with a $78 price target. Valera says the company's imminent service launch of the ViaSat-2 satellite will serve as a catalyst for Broadband subscribers. The analyst also anticipates a sharp acceleration of in-flight installs and potential announcements of additional in-flight or government wins further supporting shares.
11/10/17
NEED
11/10/17
UPGRADE
NEED
Buy
ViaSat upgraded to Buy from Hold at Needham
11/09/17
WELS
11/09/17
NO CHANGE
WELS
Outperform
ViaSat comments should move stock higher today, says Wells Fargo
Wells Fargo analyst Andrew Spinola believes Viasat last night provided a few positive data points that should drive the stock higher today. The company announced an extension and expansion of the JetBlue (JBLU) contract, which isn't a big surprise but still positive, Spinola writes in a post-earnings research note. Further, ViaSat provided some positive commentary on what to expect in Q4 and fiscal 2019, saying it can grow subscribers significantly faster in fiscal 2019 than it did during the Viasat-1 ramp, the analyst adds. He expects investors to view the commentary positively and believes the stock will begin pricing in the "significant" EBITDA ramp in front of the company. Spinola has an Outperform rating on ViaSat.
EXC Exelon
$40.80

-0.015 (-0.04%)

07/27/17
SBSH
07/27/17
UPGRADE
SBSH
Buy
Exelon upgraded to Buy from Neutral at Citi
10/11/17
GSCO
10/11/17
DOWNGRADE
Target $35
GSCO
Sell
Exelon downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Michael Lapides downgraded Exelon to Sell saying consensus earnings estimates have downside risk given weakness at the company's merchant power segment. The analyst lowered 2019/2020 forecasts by 5%-11% given lower regional natural gas/power prices. He keeps a $35 price target for the shares.
12/14/17
JPMS
12/14/17
NO CHANGE
JPMS
Overweight
Exelon removed from Analyst Focus List at JPMorgan
JPMorgan analyst Christopher Turnure removed Exelon from his firm's Analyst Focus List but keeps an Overweight rating on the shares with a $45 price target. The analyst calls PSEG (PEG) and Westar Energy (WR) his top picks in U.S. Utilities & Power heading into 2018.
12/15/17
MZHO
12/15/17
INITIATION
Target $36
MZHO
Underperform
Exelon initiated with an Underperform at Mizuho
Exelon analyst Paul Fremont initiated Exelon with an Underperform and $36 price target to reflect expected earnings pressure from weak forward gas and power prices and high debt.
ORIG Ocean Rig UDW
$24.55

-0.17 (-0.69%)

12/15/17
FBCO
12/15/17
INITIATION
Target $32
FBCO
Outperform
Ocean Rig UDW initiated with an Outperform at Credit Suisse
Credit Suisse analyst Gregory Lewis started Ocean Rig UDW with an Outperform rating and $32 price target. The company's restructuring wiped away $3.3B in debt, Lewis tells investors in a research note. The analyst expects floater utilization to pick up in 2018 and views Ocean Rig as well positioned to "ride out an extended multiyear down-cycle."
10/23/17
DNBM
10/23/17
UPGRADE
DNBM
Buy
Ocean Rig UDW upgraded to Buy from Hold at DNB Markets
FTR Frontier Communications
$8.69

-1.51 (-14.80%)

12/15/17
LEHM
12/15/17
INITIATION
Target $7
LEHM
Underweight
Frontier Communications initiated with an Underweight at Barclays
Barclays analyst Amir Rozwadowski started Frontier Communications with an Underweight rating and $7 price target. The analyst believes the company's dividend is at risk of being cut further over the near term.
12/13/17
MSCO
12/13/17
NO CHANGE
Target $21.6
MSCO
Overweight
Morgan Stanley says CenturyLink can outperform after industry's challenging 2017
Noting that 2017 was a challenging year for wireline telecom and that CenturyLink struggled to hit guidance for the third consecutive year, Simon Flannery still believes that the Level 3 merger is transformative and contends that CenturyLink's (CTL) valuation should ultimately diverge from legacy wireline peers such as Frontier (FTR) and Windstream (WIN) if the deal proves successful. If 2017 marks the trough in operational performance, CenturyLink is poised to outperform "meaningfully" next year and beyond, said Flannery, who trimmed his price target on the stock to $21.60 from $26 but maintains an Overweight rating on the shares.
11/10/17
11/10/17
DOWNGRADE
Target $4

Underperform
Frontier Communications downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst David Barden downgraded Frontier Communications to Underperform and slashed its price target to $4 from $19 due to dividend concerns. Barden said Frontier is evaluating the dividend quarter to quarter, while trying to reduce net leverage, and cannot assume with certainty that the dividends will get paid.
11/09/17
GABE
11/09/17
DOWNGRADE
GABE
Hold
Frontier Communications downgraded to Hold from Buy at Gabelli
Gabelli analyst Sergey Dluzhevskiy downgraded Frontier Communications to Hold from Buy telling investors he has increased concerns customer and revenue trends are not improving fast enough for the company to stabilize the business and deliver meaningful results. The analyst expects leverage to remain elevated over the next few years and does not expect the competitive environment to ease. Further, Dluzhevskiy said the dividend faces increased risk of being cut if management decides to reinvest in order to accelerate operating trends and or pays down debt.
RIGL Rigel Pharmaceuticals
$3.57

-0.15 (-4.03%)

11/06/17
11/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CarGurus (CARG) was initiated with a Sector Perform at RBC Capital, a Market Perform at Raymond James and JMP Securities, and a Neutral at Goldman Sachs. 2. OrthoPediatrics (KIDS) was initiated with a Buy at Stifel and BTIG while being initiated with an Overweight at Piper Jaffray. 3. Rimini Street (RMNI) initiated with an Outperform at Cowen. 4. Rigel Pharmaceuticals (RIGL) assumed with a Buy at H.C. Wainwright. 5. Great Elm Capital (GECC) initiated with a Neutral at Janney Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/14/17
CANT
12/14/17
INITIATION
Target $6
CANT
Overweight
Rigel Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor initiated Rigel Pharmaceuticals with an Overweight and $6 price target.
12/15/17
CANT
12/15/17
INITIATION
Target $6
CANT
Overweight
Cantor sees FDA approval for Rigel, starts with Overweight rating
Cantor Fitzgerald analyst Elemer Piros last night initiated Rigel Pharmaceuticals with an Overweight rating and $6 price target. The company is poised to achieve FDA approval of fostamatinib for lead indication immune thrombocytopenia, Piros tells investors in a research note. The analyst also believes fostamatinib has an attractive opportunity to expand its use with additional immune-related rare conditions autoimmune hemolytic anemia and immunoglobulin A nephropathy, both of which are in Phase 2 development.
11/06/17
HCWC
11/06/17
INITIATION
Target $7
HCWC
Buy
Rigel Pharmaceuticals assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis assumed coverage of Rigel Pharmaceuticals with a Buy rating and $7 price target. The analyst projects FDA approval of fostamatinib for the treatment of immune thrombocytopenic purpura by the April 2018 action date. He also believes that a "significant upcoming potential driver" could be the signing of a major outside the U.S. partnership for the drug.

TODAY'S FREE FLY STORIES

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.